Colorectal cancer (CRC) is the most common digestive cancer in Tunisia and in the world. Given the absence of a national cancer registry in Tunisia, the incidence of CRC is estimated based on three regional registries. According to the registry of the center of Tunisia, the standardized incidence of colon cancer is 6.5 per 100,000 inhabitants per year in men and 6.1 per 100,000 inhabitants per year in women [1] .

In the recent years, the therapeutic advances in the treatment of metastatic CRC (mCRC) have changed its natural history. In fact, the median survival of mCRC patients treated with chemotherapy including 5-Fluoro Uracil (5-FU) was between 6 and 12 months [2] , while this median survival after introduction of oxaliplatin, irinotecan and targeted therapies was prolonged up to 30 months, or even more with personalized targeted therapies based on the molecular profile of the tumor [3] . To our knowledge, this evolution has not been assessed over a long period in a same center and such evaluation would give a better idea about the progress resulting from therapeutic advances.

In this context, this study aimed to compare patients with mCRC treated at the University Hospital of Sousse (Tunisia) through three periods (1994-1998, 1999-2005 and 2006-2011) in terms of treatment strategy; objective response rate (ORR) to chemotherapy; median overall survival (OS) and prognostic factors conditioning OS.

This was a retrospective study covering the period from January 1994 to December 2011. It involved 401 patients treated in the oncological medical department of the University Hospital of Sousse and fulfilling the following inclusion criteria: histological Proof of rectal or colic adenocarcinoma and metachronous or synchronous metastases of CRC. Evaluation was done every three cycles of chemotherapy. Chemotherapy was continued until tumor progression or occurrence of severe toxicity of chemotherapy.

Chemotherapy protocols used were as follow:

-Fufol: 5-fluorouracil (5FU), 425 mg/m²/day, day1 to day 5, Folinic acid: 20 mg/m²/day, day 1 to day 5; simplified LV5FU2: folinic acid 400 mg/m² in 2 hours and 5FU 400 mg/m² in 10 min then 5 FU 2400 mg/m² as a continuous infusion of 44 hours;

-Folfiri: irinotecan 180 mg/m² + simplified LV5FU2;

-Folfox4: oxaliplatin 85 mg/m² in 2 hours + simplified LV5FU2;

-Folfirinox: 5FU, folinic acid, oxaliplatin and irinotecan,

-Capecitabine: 2500 mg/m²/j, 2 weeks by 3.

-Bevacizumab-Folfiri: Bevacizumab 5 mg/kg/15 days + Folfiri

The prognostic factors studied were: age, initial stage, general condition according to world health organization (WHO), initial liver function tests, level of the tumor marker carcinoembryonic antigen (CEA), localization of metastases, type of the first line chemotherapy, radiological response to three cycles and six cycles of first, second and third line of chemotherapy and eventual surgery of the primitive cancer and liver metastases. For some results, we divided the 401 patients into three groups: group 1 (G1) including patients treated in the period 1994-1998, group 2 (G2) including patients treated in the period 1999-2005 and group 3 (G3) including patients treated in the period 2006-2011. Periods’ choice was guided by availability of treatment which evolved over time depending on the regulations of the Tunisian country. In fact, marketing authorization was given to irinotecan in 1998, to oxaliplatinin 2002 andto bevacizumab in 2010. According to these dates and practice findings, we considered that the G1 patients were treated mainly with 5FU, the G2 patients were treated mainly with irinotecan and G3 patients were treated with oxaliplatine and to lesser extent with bevacizumab.

The date of inclusion considered was that when histological diagnosis was made by biopsy or surgery if metastases were synchronous, and that when at least one metastasis was confirmed if it was metachronous. Median follow-up was 74 months for the groups 1 and 2 together (G1-2) and 63.55 months for G3.

Statistical analyses were performed using SPSS 18.0 software. Dependent variables examined were the response to first line of chemotherapy and OS. The main determinants of ORR were examined using univariate analysis with chi 2 test for comparison of percentages and t Student test or Anova test for equality of means. OS curves were calculated according to the Kaplan-Meier method and between-group comparisons were performed using the log-rank test. In a multivariate analysis, the variables that are statistically associated with a 0.2 threshold were introduced into cox regression model. For all results, a p value less than 0.05 was considered as statistically significant.

The surgery of the primary tumor is classically indicated for complications of mCRC (tumor bleeding, perforation or obstruction) especially when the complication does not resolve with other therapeutic options (endoscopic stunt, percutaneous embolization, etc.), but its role remains controversial in asymptomatic mCRC [4] [5] . Indeed, there was no significant increase in gastrointestinal complications during chemotherapy for non-op- erated primary tumors and it has been advanced that if surgery of the primary tumor is avoided, we could spare the patient the morbidity and mortality associated with surgery [6] and delayed start of chemotherapy [7] .

In a meta-analysis of 7 uncontrolled studies published in 2010 comparing surgical treatment with chemotherapy for mCRC, the authors concluded that surgery does not reduce the risk of complications from the primary tumor [8] . Despite these data, and although only 5% to 15% of patients with mCRC may have a curative surgery for their primary tumor as well as metastasis, up to 75% of patients undergo surgical resection of their primary tumor [5] . In the present study, surgery of the primary tumor was performed in 68% of cases for G1-2 and in 85% of cases for G3 and it was associated with a significant increase in OS for G3 (p = 0.001). A more recent meta-analysis of 8 retrospective studies published in 2012, resection of the primary tumor was associated with longer survival with a median gain of OS estimated around 6 months [4] . In this study, the gain was estimated at 9 months in G3 (5.88 months versus 15.05 months, p = 0.001). In accordance with these results, in a study by Ferrand et al [5] published in 2013, 72% of patients were operated with a significant gain in OS (16.3 months versus 19.2 months, p < 0.0001).

Among patients with liver metastases, only 10% to 20% may benefit from surgical resection [9] . In our patients, this rate remains low but tends to increase (16% for G1-2 versus 19.6% for G3). This surgery was

N: number of patients, G1-G2: group of patients treated between 1994 and 2005, G3: group of patients treated between 2006 and 2011, mOS: median overall survival, ORR: objective response rate, CT: chemotherapy.

described as the best treatment allowing a survival rate at 5 years up to 40% [4] . Similarly in this study, surgery of liver metastases was significantly associated with better OS (p < 0.05 for G1-2, p = 0.016 for G3).

In the last few years, chemotherapy protocols have multiplied with an increase in terms of efficacy and tolerance. The therapeutic introduction of new cytotoxic agents with effective antitumor activity in mCRC has led to the change of some therapeutic strategies [10] . This study revealed that since 1994, there was a significant improvement in OS with transition of treatment of mCRC from 5 FU alone to its combination with irinotecan oroxaliplatin and with targeted therapies. These survival rates tend to reach those reported in Western studies [11] [12] .

Irinotecan and oxaliplatin have completely changed the therapeutic approach of mCRC [10] [13] [14] . The therapeutic strategy is not univocal. Some authors advocate that all patients with mCRC should be given chemotherapy containing oxaliplatin or irinotecan as a first line therapy. Other authors state that if liver metastases are never resectable and if the cancer is not very progressive (i.e. not a bulky tumor; minimally symptomatic metastases; conserved general condition with a WHO score of 0, or if the general condition is impaired, this is due to age or comorbidities), it is possible to initiate treatment with fluoropyrimidine ± bevacizumab and to establish bitherapy in second-line treatment (escalation therapeutic strategy) [15] .

The use of targeted therapies in mCRC is now becoming crucial, especially since improved survival for wild ras tumors up to 33 months [3] has been reported. Two targeted therapies, bevacizumab and cetuximab, had the marketing authorization in Tunisia by 2010 and 2012, respectively. This may explain the low rates of patients having targeted therapy in this study (Folfiri associated with Bevacizumab in 2% of cases) and incites for the study and analysis of a new period including patients treated with these molecules.

Finally, some limitations need to be noted. In fact, this was a retrospective study, the medical records were incomplete in some cases and the latest news of the patients were not always found. In addition, this study included a period of 12 years, thus creating very heterogeneous groups in terms of treatment options.

Development of medical and surgical therapeutic strategies resulted in improved survival for patients with mCRC in the center of Tunisia. Within the limits of a retrospective study, our results are comparable to those reported in other studies in terms of therapeutic results and prognostic factors [16] . For the coming years, personalized medicine with treatments targeting the molecular defect and thus allowing avoidance of treatments potentially toxic and ineffective, in addition to progress being made in the fields of genetics, proteomics, medical imaging, and medical therapy, will be challenging but surely beneficial.

The authors declare that there is no conflict of interest regarding the publication of this paper.

Amira Daldoul,Olfa Gharbi,Laila Ben Fatma,Imene Chabchoub,Sonia Zaied,Khaled Ben Ahmed,Faten Ezzairi,Makrem Hochlef,Imtinene Belaid,Sami Limem,Slim Ben Ahmed, (2016) Metastatic Colorectal Cancer: Evolution of the Response Rate and Survival with Therapeutic Progress. Open Journal of Gastroenterology,06,127-135. doi: 10.4236/ojgas.2016.65017